September 22, 2017 10:35 AM EDT

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

Shehla Shakoor

Managing Director

⇨ AbbVie wants to explore how a combination of its anti-c-Met antibody drug ABBV-399 will work in combination with Bristol-Myers’ Opdivo in treating non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Ab­b­Vie part­ners on an Op­di­vo com­bo study with Bris­tol-My­ers; In­ter­cept tum­bles on FDA warn­ing

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?